While targeting TGFβR2-mutant tumors exposes vulnerabilities to stromal TGF-β blockade in pancreatic cancer, canonical TGF-β signaling suppresses epithelial pancreatic cancer (PDA) cell proliferation, and as a result, inhibiting TGF-β has not been successful [11]. This evidence concerns the gene TGFB1 and pancreatic neoplasm.